Navigation Links
Chimerix to Present at Cowen and Company's 32nd Annual Health Care Conference
Date:3/5/2012

RESEARCH TRIANGLE PARK, N.C., March 5, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced that Kenneth I. Moch, President and Chief Executive Officer, will present at Cowen and Company's 32nd Annual Health Care Conference on Tuesday, March 6, 2012 at 3:00 pm ET at The Boston Marriott Copley Place in Boston, Massachusetts.

Mr. Moch's presentation will include an update on the company's clinical pipeline, which includes its lead development program, CMX001.  CMX001 is being tested in ongoing placebo-controlled clinical trials and in open-label treatment protocols for the prophylaxis, preemption and treatment of double-stranded DNA viruses (dsDNA) viruses, including herpesviruses and adenoviruses, and as a potential biodefense countermeasure in the event of a smallpox release. CMX001 recently announced results for Study 201, a Phase 2 double-blind, placebo-controlled trial which evaluated the safety, tolerability and ability of CMX001 to prevent or control cytomegalovirus (CMV) disease in 230 CMV-seropositive allogeneic stem cell transplant recipients. CMX001 had a statistically significant benefit versus placebo in preventing CMV viremia and/or CMV disease 13 weeks post-transplant. These data were presented during the "Best Abstracts Plenary Session" at the 2012 BMT Tandem Meetings on February 3rd in San Diego.

About Chimerix

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health. Utilizing proprietary lipid conjugate technology, the company's two clinical stage compounds have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs.

The company's lead candidate, CMX001, is a Lipid-Antiviral-Conjugate that delivers high intracellular levels of the active antiviral agent cidofo
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
3. Chimerix to Present at Two Upcoming Investor Conferences
4. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
5. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
6. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
7. Chimerix to Present at 9th Annual BIO Investor Forum
8. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
9. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
10. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
11. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 21, 2014 Abaxis, Inc. (NasdaqGS: ... analysis systems, today reported financial results for the second ... quarter overview: , Revenues of $53.9 million, up ... EPS of $0.24, up 33% over last year,s comparable ... from Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 million, ...
(Date:10/22/2014)... , Oct. 22, 2014 Sanomedics International Holdings, ... report by Global Research & Data Services, demand for ... from 2014 through 2018, as demand for more accurate ... is the world,s largest market for thermometers, and ... thermometers is Sanomedics International Holdings, Inc. Sanomedics ...
(Date:10/22/2014)... REDWOOD CITY, Calif. , Oct. 22, 2014 ... ) today announced that results from the  IAP310 ... and Pain Medicine (RAPM), a peer-reviewed journal ... placebo-controlled, Phase 3 trial evaluating the safety and ... sufentanil sublingual tablet system (SSTS), for the treatment ...
Breaking Medicine Technology:Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2
... WASHINGTON, Feb. 9, 2012   The Pharmaceutical Care ... in Pennsylvania that highlights the core value proposition of pharmacy ... What PBMs Do" – focuses on key themes ... and consumers. , PBM mail-service pharmacies improve safety, savings, ...
... Feb. 9, 2012  As part of its ongoing restructuring ... of its subsidiaries as wholly owned subsidiaries of iMD ... time, a wholly owned subsidiary of Optimum Mobile Imaging ... Hyper-Interactive Marketing LLC, will now reside alongside the newly ...
Cached Medicine Technology:PCMA Launches New Pennsylvania Ad Campaign: 'That's What PBMs Do' 2Optimum Mobile Imaging Corp. (ICBU) Retains Securities Law Firm 2
(Date:10/22/2014)... Lintelus, Inc., an event software provider, ... Sales, will be speaking on the subject of “Event ... October 28, at the Holiday Inn in New York ... well as a Tech Demo at 12:45pm, to educate ... more engaging event experience. , The Annual Meetings Technology ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... women undergoing in vitro fertilization (IVF) are only about half ... popular assisted reproduction technique, new research indicates, and the racial ... the study, about 31 percent of white patients became pregnant ... Analyzing more than 4,000 IVF cycles over two years ...
(Date:10/22/2014)... (HealthDay News) -- Measures taken by Firestone officials at ... may have limited the spread of the disease there ... Firestone Natural Rubber Co. provides health services to about ... densely populated communities. Between Aug. 1 and Sept. ... among those 80,000 people. That incidence rate of 0.09 ...
(Date:10/20/2014)... October 20, 2014 With a mere ... Charlie Crist made a brief fundraising stop at the ... Thursday. , Fresh from a debate last night with ... the stage for the first seven minutes because Crist ... governor described the incident in one word: "weird." , ...
(Date:10/20/2014)... October 20, 2014 Women’s health specialist, ... Obstetrics & Gynecology of Columbus, Inc., A Division of ... services to more than 100,000 patients annually. Dr. Murphy ... ages and stages of a women’s life. She is ... in Westerville and Dublin. , Dr. Murphy offers ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3
... Die of CancerCancer is the Number One Cause of Death in Dogs ... 13 Dog owners and lovers in the United States ... They are correct. One in four dogs die ... over the age of 2. Morris Animal Foundation (MAF) ...
... Winter Weather Compound January,s Blood Drain NEW YORK, Jan. ... regional operations (serving New York City, Long Island, Hudson ... for blood donations. Hospital demand for blood (needed ... expectations while levels of blood donation have been below ...
... 13 /PRNewswire/ - Researchers at the University of ... vessels in damaged muscle tissue by injecting a biomaterial ... Blood vessel regeneration suggests that the body,s own cells ... and restore function. , Details of the regeneration process ...
... 13 Imagine that you have just arrived,on your night ... whom,you are responsible. Of those, two speak only Spanish. ... Spanish-speaking family members gathered,around the patient,s door and they appear ... the patient,s family and the hospital medical staff try, in ...
... at the University of Liverpool have developed a new dental ... is visible to the human eye. , The toothbrush-sized product ... around the mouth and viewed through yellow glasses with a ... red glow. The device, produced in collaboration with dental and ...
... SCOTTSDALE, Ariz., Jan. 13 After helping thousands ... spinal,surgery at their flagship facility in Tampa, the ... new center in Scottsdale, Arizona. LSI is,revolutionizing the ... 5-day process from surgery to recovery, drastically reducing ...
Cached Medicine News:Health News:Canine Cancer #1 Fear of Dog Lovers, Web Exclusive by Morris Animal Foundation Provides News on Latest Breakthroughs - Crucial Facts for Dog Owners 2Health News:Canine Cancer #1 Fear of Dog Lovers, Web Exclusive by Morris Animal Foundation Provides News on Latest Breakthroughs - Crucial Facts for Dog Owners 3Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 2Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 3Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 4Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 5Health News:University of Ottawa Heart Institute Scientists Successfully Develop Novel Biomaterial to Help Grow New Blood Vessels 2Health News:University of Ottawa Heart Institute Scientists Successfully Develop Novel Biomaterial to Help Grow New Blood Vessels 3Health News:Command Spanish Online offers Healthcare Spanish Anytime, Anywhere, and at Your Own Pace 2Health News:Leaders in Minimally Invasive Spinal Surgery Open New Facility in Scottsdale 2Health News:Leaders in Minimally Invasive Spinal Surgery Open New Facility in Scottsdale 3
... SPECIFICATIONS Appearance/Form: White to buff-colored powder Activity: >=590g of ... (A&B): Passes tests Limit of Methanol: Specific Rotation ... pH (4%, H 2 O): 3.5 to 5.5 Loss ... C 1 : 25-50% C 2 + C ...
Gentamicin is a selection antibiotic used for selection of a Bac-to-Bac recombinant expression bacmid following transposition. Gentamicin is provided as a solution at a concentration of 50 mg/ml....
Gentamicin is an aminoglycosidic antibiotic that inhibits bacterial growth by inhibiting protein synthesis. Gentamicin is used for prevention and elimination of bacterial contaminants in cell culture...
1.0% Tryptone, 0.5% yeast extract, 0.5% Sodium Chloride, 0.6% agarose....
Medicine Products: